SSY Group Secures Key Drug Approvals in China
SSY Group (HK:2005) has released an update. SSY Group Limited has received approval from the National Medical Products Administration of China ...
Medscape1 个月
Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study)
One thousand eight hundred and eighty-eight patients with a mean age of 59 years (range 11 100 years) were treated with lornoxicam, and 632 patients with a mean age of 61 years (range 14 97 ...
Medscape1 个月
Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study)
Lornoxicam is a strong analgesic and anti-inflammatory NSAID with balanced cyclo-oxygenase (COX)-1/COX-2 inhibition and excellent tolerability. In the course of the development of selective COX-2 ...